Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease

Barcelona, Spain, September 8, 2026 – Orikine Bio (“Orikine”), a biotechnology company pioneering bi-specific cytokines to reprogram the immune system and treat autoimmune and chronic inflammatory disease, today announced changes to its leadership team to support the next stage of corporate development. Sabrina Kuttruff-Coqui, Ph.D., has been appointed Chief Executive Officer, and Joachim Koch, Ph.D., has been appointed Chief Scientific Officer and Chief Development Officer. Both bring decades of biotechnology industry experience to accelerate Orikine's growth strategy and advance Orikine's pipeline. Andreas Muehler, MD, MBA, joins as part-time Chief Medical Officer, bringing a strong medical track record for the transition of lead candidate ORK1 toward an IND submission and first-in-human studies. Pilar Casado García will continue to serve as Chief Financial Officer, ensuring financial and institutional continuity. The Orikine team is expanding at a critical inflection point, as ORK1 advances from preclinical research to IND-enabling studies in inflammatory bowel disease.